CMV CTLs
Phase 2Biologic
CMV CTLs is one of 27 biologic programs targeting Cytomegalovirus Infection. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Cytomegalovirus Infection
#DrugCompanyPhaseTrials
1Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Vistide
GileadApproved
Hepsera
GileadApproved
Afinitor
NovartisApproved
Lanoxin
AAdvanz Pharma
Approved
Carnitor
LLeadiant Biosciences, Inc.
Approved
Artesunate
AAmivas Inc.
Approved
Cytovene
EExela Pharma Sciences, LLC.
Phase 3
Livtencity
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CMV CTLs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details